Shunyuan Construction plans to withdraw from Haibao Life Insurance Haima Group to become the single largest shareholder Post date May 17, 2022 — 12:40 Post Lock Read More Haibao Life's shareholder lineup made waves for the first time, and Haima Group plans to win the "dominance"- Post date May 16, 2022 — 21:59 Post Lock Read More Weixinkang has been surveyed by 5 institutions: In the future, with the gradual increase in the coverage of 12V hospitals, it will bring continuous business growth to the company, which is the first curve of business growth (with survey questions and answers) Post date May 16, 2022 — 12:55 Post Lock Read More Shunyuan Construction plans to withdraw, Haima Group will become the largest shareholder of Haibao Life Insurance Post date May 16, 2022 — 08:49 Post Lock Read More After changing the "new coach", Haibao Life Insurance's shareholder lineup has changed again. Shunyuan Construction plans to liquidate its equity and Haima Investment's largest shareholder Blue Whale Finance Post date May 16, 2022 — 08:48 Post Lock Read More Shareholders of Haibao Life Insurance will change: Shunyuan Construction plans to withdraw, and Haima Group will become the largest shareholder – yqqlm Post date May 14, 2022 — 02:32 Post Lock Read More [Express] 12 stocks facing selling pressure on Friday, 2.89 billion shares lifted CFi.CN Zhongcai Network Post date May 12, 2022 — 18:30 Post Lock Read More Announcement of Haisco Pharmaceutical Group Co., Ltd. on changing the company's registered capital and amending the "Articles of Association" Post date May 9, 2022 — 05:28 Post Lock Read More Haisco: Net profit in the first quarter of 2022 is about 26.2 million yuan, a year-on-year decrease of 90.88% – yqqlm Post date April 28, 2022 — 18:45 Post Lock Read More Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Haibao Life's shareholder lineup made waves for the first time, and Haima Group plans to win the "dominance"- Post date May 16, 2022 — 21:59 Post Lock Read More Weixinkang has been surveyed by 5 institutions: In the future, with the gradual increase in the coverage of 12V hospitals, it will bring continuous business growth to the company, which is the first curve of business growth (with survey questions and answers) Post date May 16, 2022 — 12:55 Post Lock Read More Shunyuan Construction plans to withdraw, Haima Group will become the largest shareholder of Haibao Life Insurance Post date May 16, 2022 — 08:49 Post Lock Read More After changing the "new coach", Haibao Life Insurance's shareholder lineup has changed again. Shunyuan Construction plans to liquidate its equity and Haima Investment's largest shareholder Blue Whale Finance Post date May 16, 2022 — 08:48 Post Lock Read More Shareholders of Haibao Life Insurance will change: Shunyuan Construction plans to withdraw, and Haima Group will become the largest shareholder – yqqlm Post date May 14, 2022 — 02:32 Post Lock Read More [Express] 12 stocks facing selling pressure on Friday, 2.89 billion shares lifted CFi.CN Zhongcai Network Post date May 12, 2022 — 18:30 Post Lock Read More Announcement of Haisco Pharmaceutical Group Co., Ltd. on changing the company's registered capital and amending the "Articles of Association" Post date May 9, 2022 — 05:28 Post Lock Read More Haisco: Net profit in the first quarter of 2022 is about 26.2 million yuan, a year-on-year decrease of 90.88% – yqqlm Post date April 28, 2022 — 18:45 Post Lock Read More Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weixinkang has been surveyed by 5 institutions: In the future, with the gradual increase in the coverage of 12V hospitals, it will bring continuous business growth to the company, which is the first curve of business growth (with survey questions and answers) Post date May 16, 2022 — 12:55 Post Lock Read More Shunyuan Construction plans to withdraw, Haima Group will become the largest shareholder of Haibao Life Insurance Post date May 16, 2022 — 08:49 Post Lock Read More After changing the "new coach", Haibao Life Insurance's shareholder lineup has changed again. Shunyuan Construction plans to liquidate its equity and Haima Investment's largest shareholder Blue Whale Finance Post date May 16, 2022 — 08:48 Post Lock Read More Shareholders of Haibao Life Insurance will change: Shunyuan Construction plans to withdraw, and Haima Group will become the largest shareholder – yqqlm Post date May 14, 2022 — 02:32 Post Lock Read More [Express] 12 stocks facing selling pressure on Friday, 2.89 billion shares lifted CFi.CN Zhongcai Network Post date May 12, 2022 — 18:30 Post Lock Read More Announcement of Haisco Pharmaceutical Group Co., Ltd. on changing the company's registered capital and amending the "Articles of Association" Post date May 9, 2022 — 05:28 Post Lock Read More Haisco: Net profit in the first quarter of 2022 is about 26.2 million yuan, a year-on-year decrease of 90.88% – yqqlm Post date April 28, 2022 — 18:45 Post Lock Read More Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shunyuan Construction plans to withdraw, Haima Group will become the largest shareholder of Haibao Life Insurance Post date May 16, 2022 — 08:49 Post Lock Read More After changing the "new coach", Haibao Life Insurance's shareholder lineup has changed again. Shunyuan Construction plans to liquidate its equity and Haima Investment's largest shareholder Blue Whale Finance Post date May 16, 2022 — 08:48 Post Lock Read More Shareholders of Haibao Life Insurance will change: Shunyuan Construction plans to withdraw, and Haima Group will become the largest shareholder – yqqlm Post date May 14, 2022 — 02:32 Post Lock Read More [Express] 12 stocks facing selling pressure on Friday, 2.89 billion shares lifted CFi.CN Zhongcai Network Post date May 12, 2022 — 18:30 Post Lock Read More Announcement of Haisco Pharmaceutical Group Co., Ltd. on changing the company's registered capital and amending the "Articles of Association" Post date May 9, 2022 — 05:28 Post Lock Read More Haisco: Net profit in the first quarter of 2022 is about 26.2 million yuan, a year-on-year decrease of 90.88% – yqqlm Post date April 28, 2022 — 18:45 Post Lock Read More Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
After changing the "new coach", Haibao Life Insurance's shareholder lineup has changed again. Shunyuan Construction plans to liquidate its equity and Haima Investment's largest shareholder Blue Whale Finance Post date May 16, 2022 — 08:48 Post Lock Read More Shareholders of Haibao Life Insurance will change: Shunyuan Construction plans to withdraw, and Haima Group will become the largest shareholder – yqqlm Post date May 14, 2022 — 02:32 Post Lock Read More [Express] 12 stocks facing selling pressure on Friday, 2.89 billion shares lifted CFi.CN Zhongcai Network Post date May 12, 2022 — 18:30 Post Lock Read More Announcement of Haisco Pharmaceutical Group Co., Ltd. on changing the company's registered capital and amending the "Articles of Association" Post date May 9, 2022 — 05:28 Post Lock Read More Haisco: Net profit in the first quarter of 2022 is about 26.2 million yuan, a year-on-year decrease of 90.88% – yqqlm Post date April 28, 2022 — 18:45 Post Lock Read More Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Shareholders of Haibao Life Insurance will change: Shunyuan Construction plans to withdraw, and Haima Group will become the largest shareholder – yqqlm Post date May 14, 2022 — 02:32 Post Lock Read More [Express] 12 stocks facing selling pressure on Friday, 2.89 billion shares lifted CFi.CN Zhongcai Network Post date May 12, 2022 — 18:30 Post Lock Read More Announcement of Haisco Pharmaceutical Group Co., Ltd. on changing the company's registered capital and amending the "Articles of Association" Post date May 9, 2022 — 05:28 Post Lock Read More Haisco: Net profit in the first quarter of 2022 is about 26.2 million yuan, a year-on-year decrease of 90.88% – yqqlm Post date April 28, 2022 — 18:45 Post Lock Read More Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
[Express] 12 stocks facing selling pressure on Friday, 2.89 billion shares lifted CFi.CN Zhongcai Network Post date May 12, 2022 — 18:30 Post Lock Read More Announcement of Haisco Pharmaceutical Group Co., Ltd. on changing the company's registered capital and amending the "Articles of Association" Post date May 9, 2022 — 05:28 Post Lock Read More Haisco: Net profit in the first quarter of 2022 is about 26.2 million yuan, a year-on-year decrease of 90.88% – yqqlm Post date April 28, 2022 — 18:45 Post Lock Read More Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Announcement of Haisco Pharmaceutical Group Co., Ltd. on changing the company's registered capital and amending the "Articles of Association" Post date May 9, 2022 — 05:28 Post Lock Read More Haisco: Net profit in the first quarter of 2022 is about 26.2 million yuan, a year-on-year decrease of 90.88% – yqqlm Post date April 28, 2022 — 18:45 Post Lock Read More Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Haisco: Net profit in the first quarter of 2022 is about 26.2 million yuan, a year-on-year decrease of 90.88% – yqqlm Post date April 28, 2022 — 18:45 Post Lock Read More Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Haisco: Net profit in 2021 is about 345 million yuan, a year-on-year decrease of 45.8% – yqqlm Post date April 26, 2022 — 20:58 Post Lock Read More Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Haisco (002653.SZ) released its 2021 results, with a net profit of 345 million yuan, a year-on-year decrease of 45.8%, and a distribution of 1.85 yuan for every 10 shares. Post date April 26, 2022 — 20:56 Post Lock Read More On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
On April 25, Haisco hit a new 60-day low in intraday trading, and the 2021 annual report of Wells Fargo Tianhui Growth Mixed A/B (LOF) Fund heavily held the stock._Stock News_Market Gold Online Post date April 25, 2022 — 17:10 Post Lock Read More Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Haisco: From 2022 to 2023, the company plans to submit and receive no less than 3 drug IND applications every year Post date April 19, 2022 — 16:35 Post Lock Read More R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
R&D investment of over 20 million yuan, a parenteral nutrition preparation of Hengrui Medicine was approved for marketing Post date April 19, 2022 — 14:51 Post Lock Read More Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hisco's new drug is approved for clinical trials in the United States for the treatment of B-cell lymphoma Post date April 15, 2022 — 19:20 Post Lock Read More The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
The first domestic oral drug for the new crown is getting closer and closer, and the research and development of the nasal spray for the new crown is accelerating Post date April 15, 2022 — 06:28 Post Lock Read More Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Haisco (002653.SZ) Obtained the "Clinical Trial Approval Notice" of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 19:47 Post Lock Read More Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Haisco (002653.SZ) obtained HSK36273 "Drug Clinical Trial Approval Notice" for innovative drug injection Post date April 10, 2022 — 19:24 Post Lock Read More Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Haisco (002653.SZ) Obtained the Approval Notice for Clinical Trial of HSK36273 for Innovative Drug Injection_Individual Stock Information_Market_Zhongjin Online Post date April 10, 2022 — 18:57 Post Lock Read More Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Haisco: HSK36273 for innovative drug injection approved for clinical trials_Oriental Fortune Post date April 10, 2022 — 17:59 Post Lock Read More
Caishen.CoCaishen.Co